Inflammatory Mechanisms in Acute Coronary Syndromes: From Pathophysiology to Therapeutic Targets.

There was also less microvascular obstruction in the tocilizumab group, although the difference in final infarct size did not reach statistical significance.

also in 111,027 other papers